Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more
Belite Bio, Inc (D01) - Total Liabilities
Latest total liabilities as of September 2025: €8.31 Million EUR
Based on the latest financial reports, Belite Bio, Inc (D01) has total liabilities worth €8.31 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Belite Bio, Inc - Total Liabilities Trend (2021–2024)
This chart illustrates how Belite Bio, Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Belite Bio, Inc Competitors by Total Liabilities
The table below lists competitors of Belite Bio, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Life Insurance Corporation Of India
NSE:LICI
|
India | ₹50.60 Trillion |
|
Frasers Logistics & Commercial Trust
PINK:FRLOF
|
USA | $3.07 Billion |
|
EZconn Corp
TW:6442
|
Taiwan | NT$5.03 Billion |
|
Country Garden Holdings Company Ltd
PINK:CTRYF
|
USA | $885.41 Billion |
|
DWS Group GmbH & Co. KGaA
XETRA:DWS
|
Germany | €4.16 Billion |
|
Yihai Kerry Arawana Holdings Co Ltd
SHE:300999
|
China | CN¥129.32 Billion |
|
Cargotec Corporation
PINK:CYJBF
|
USA | $1.33 Billion |
|
Silvercorp Metals Inc
NYSE MKT:SVM
|
USA | $505.09 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Belite Bio, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 34.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Belite Bio, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Belite Bio, Inc (2021–2024)
The table below shows the annual total liabilities of Belite Bio, Inc from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €6.31 Million | +49.87% |
| 2023-12-31 | €4.21 Million | +51.91% |
| 2022-12-31 | €2.77 Million | -91.71% |
| 2021-12-31 | €33.44 Million | -- |